Objective: To determine the potential drug-drug interactions between anti-malarial candidate 97/78 and anti-tubercular drug rifabutin in-vivo in rats followed by in-vitro investigation of the underlying mechanisms of drug interaction. Methods: Single oral dose study was conducted in male and female rats at 40 mg/kg and 70 mg/kg for 97/78 and rifabutin respectively. Results: It was reported that rifabutin co-administration altered pharmacokinetics of 97/ 63 (active metabolite of 97/78). A significant decrease was reported in the systemic exposure of 97/63 by a factor of 3-4. The AUC 0-last values were (4.03 ± 0.60) and (5.44 ± 1.15) mg h mL −1 upon 97/78 administration alone, while the values were decreased to (1.13 ± 0.10) and (1.23 ± 1.13) mg h mL −1 upon rifabutin co-administration in male and female rats respectively. Statistically significant differences were also reported in C max and T max values upon rifabutin co-administration. In-vitro drug metabolism study in rat liver microsomes has shown that the metabolism of 97/63 was increased by 10%-12% upon rifabutin co-incubation. The extent of plasma protein binding of 97/63 was found to be decreased from 54%-55% to 6%-8% upon rifabutin addition. Conclusions: It was concluded that rifabutin co-administration altered PK parameters of 97/63 in SD rats. However, no intersex influences were reported in the interaction pattern. The results obtained in the in-vivo study were well correlated with the in-vitro findings and can further be applied to explore other aspects of potential drug interactions between these two drugs.
Introduction
Tuberculosis and malaria co-epidemics are very prevalent in most of the tropical and sub-tropical areas of the world that creates serious damage to socio-economic status besides public health concerns. More than six million people are killed by the co-infection of these two diseases with AIDS annually [1] [2] [3] . Patients are supposed to take co-medications for malaria and tuberculosis simultaneously, which may give rise to serious drug-drug interactions (DDIs). It has been reported that the greater the number of drugs is given to a patient, the more the risk of potential drug interactions. Incidences of such drug interactions raises up to 7% in those patients taking 6-10 drugs and 40% in those taking 16-20 drugs daily [4] .
It is important to explore drug metabolism and pharmacokinetic (DMPK) properties of drug candidate in early stages of drug discovery and development. Besides DMPK, DDIs are routinely incorporated in the early phases of drug development pathway from a safety point of views. For this, preclinical studies are often carried out in experimental animals. From the preclinical data, the allometric scaling approaches that consider important anatomical and physiochemical variables in higher species as a power function of the body weight across species may be used to predict human pharmacokinetics (PK) aspects [5] [6] [7] [8] . There are a number of gender-dependent and gender-specific characteristics that are known to influence the PK of a drug. Physiological and anatomical differences between the genders of a species are the responsible factors influencing PK of a drug differently [9, 10] .
In the present study, in-vivo drug interactions were investigated between a novel trioxane anti-malarial candidate 97/78 (phase I clinical trials completed) and antitubercular drug rifabutin (interacting drug). Single oral dose drug interaction studies were performed in male and female Sprague Dawley (SD) rats to determine the changes in PK and intersexual interaction pattern of 97/78 upon rifabutin co-administration. The results of single dose interaction study were analyzed and in-vitro studies were performed to find out the mechanism behind the existence of these in-vivo interactions.
Materials and methods

Chemicals
Rifabutin was obtained as a gift sample from Lupin (Pune), India. Reference standards (purity > 98%) of 97/78, 97/63 ( Figure 1a ) and internal standard (IS) arteether ( Figure 1b) were obtained from the medicinal chemistry division, CDRI, Lucknow, India. Blank plasma was collected from drug free healthy male and female SD rats procured from the Laboratory Animal Services Division, CDRI. All other chemicals and reagents were of analytical liquid chromatographic (LC) grade. Dextran coated charcoal for plasma protein binding study was obtained from Sigma chemicals USA. Dulbecco's Phosphate buffered saline (Ca 2+ and Mg 2+ free) was purchased from Hi media Lab. Pvt.
Ltd., Mumbai. For metabolism stability studies, Tris (hydroxymethyl) aminomethane (tris base), KCl, MgCl 2 $6H 2 O, bovine serum albumin and a reduced form of b-nicotinamide adenine dinucleotide phosphate were purchased from Sisco Research Laboratory (Mumbai, Maharashtra, India). 1-aminobenzotriazole, Bradford reagent and diethyl ether were procured from Qualigens (Mumbai), Loba Chemie (Mumbai) and TKM Pharma (Hyderabad, AP, India), respectively. Rat liver microsomes were prepared by using the methods adapted from literature [11] .
Subjects and study design
Healthy male and female SD rats (250-270 g) free from any symptoms of pathophysiology were obtained from Laboratory Animal Services Division, CDRI (approval no. IAEC/2012/ 91Ns) were allowed to acclimatize for 3 d in ventilated polypropylene cases at standard laboratory conditions [12 
In-vivo studies
We conducted a parallel design, single dose/single dose pharmacokinetic interaction study that comprised of two groups of animals. One group of subjects was orally administered with 97/78 at 40 mg/kg, while other group received 97/ 78 followed by rifabutin at 40 mg/kg dose. Sparse sampling approach was used to collect blood samples through cardiac puncture (first sample) and inferior vena cava (terminal sample). Blood samples were collected before dosing (0 time point) and up to 96 h post dose. Blood samples were stored in ice until centrifugation. Plasma was separated by centrifugation at 2 200 g for 5 min and stored at −60 C until analysis.
Analysis was performed within a month of sample collection. All experimental procedures were approved and performed in accordance with the guidelines of the Institutional Animal Experimentation Ethics Committee (IAEC/CPCSEA/Regulatory Agencies). The formulations used in the study were aqueous suspension of 97/78 and rifabutin in 0.25% carboxy methyl cellulose. Both the formulations were subjected to quality control checks to ensure strength and content uniformity. The strength of the formulations for 97/78 and rifabutin was 20 and 35 mg/mL respectively.
In-vitro studies
In-vitro studies were then conducted to find out the mechanism behind the in-vivo study observations. In-vitro plasma protein binding studies were conducted to find out the changes in the plasma protein bindings of 97/78, while in-vitro drug metabolism studies were conducted to find out the interactions at the level of metabolism.
Protein binding was estimated using modified charcoal adsorption method adopted from literature [12] . The study was conducted in three replicates each at 100 and 1 000 ng/mL 
Pharmacokinetic sample processing and bioanalysis
All study samples were quantitatively estimated for the determination of 97/63 (active metabolite of 97/78). A partially validated method in Q-trap 5500 LC-MS/MS mass spectrometer (Applied Biosystems, MDS Sciex, USA) with Analyst 1.6 software was used to determine plasma concentration of 97/63. The assay was linear over the range 0.625-80 ng/mL 10 mL of IS was spiked into each study sample followed by a single step protein precipitation method using acetonitrile. Mass spectrometry was performed in positive mode electro spray ionization with capillary voltage 5.5 KV. The MS/MS transitions of m/z 418.2 / 119.1 and 330.3 / 267.4 were used to quantify 97/63 and IS respectively. HPLC elution was carried out in isocratic mode with mobile phase comprising of 80:20 (v/v) ACN (0.1% formic acid) and ammonium acetate buffer (10 mM, pH 4.0) using a Phenomenex C 18 Columbus (50 mm × 2 mm, 5 m particle size) equipped with a security guard cartridge. Separation was achieved at 450 mL/min flow rate with injection volume of 10 mL [13, 14] . Processed sample were maintained in auto sampler at 4 C.
Statistical analysis
The study endpoints examined were area under the curve (AUC 0-last ), maximum plasma concentration (C max ), time to attain C max (T max ), elimination half life (T 1/2 ) and mean residence time (MRT) and the relative bioavailability (RB). The PK parameters were calculated by non-compartmental analysis using Winnonlin software (Version 1.5, Pharsight Corporation). All results were expressed as mean ± SEM. RB was calculated as:
The results of the in-vitro metabolic study were expressed as the % drug remaining, which was calculated as: % Drug remaining = drug conc: after incubation drug conc: at t = 0 × 100 (2)
The % plasma protein binding was calculated as, % Plasma protein binding = Drug conc: analyzed at t = 0 Spiked plasma conc: × 100 (3)
It has been reported that 97/78 (prodrug) converts into 97/63 (active metabolite) within a few minutes in biological matrices like plasma [15] , thus samples were analyzed for the determination of 97/63, post 97/78 oral dose administration alone and with rifabutin in male and female rats. All the results are expressed as mean values ± SEM, n = 4. The values of various PK parameters for 97/78 alone and coadministration with rifabutin were statistically compared with '2-tailed Students t-test'. The values were considered statistically significantly different for P < 0.05.
Results
Pharmacokinetic drug interaction studies
3.1.1. Male rats Table 1 summarizes PK parameters of 97/63 post 97/78 administration alone and with rifabutin in male rats. The value of C max was (0.56 ± 0.18) mg/mL at corresponding T max of (5.33 ± 0.76) h when 97/78 was given alone. While upon coadministration with rifabutin these values were found (0.13 ± 0.03) mg/mL and (1.83 ± 1.25) h for C max and T max respectively. Figure 2 represents plasma concentration-time profile of 97/63, when 97/78 was given alone and in combination with rifabutin in male rats. Table 1 summarizes PK parameters of 97/63 post 97/78 administration alone and with rifabutin in female rats. The value of C max was (0.79 ± 0.10) mg/mL at corresponding T max of (6.00 ± 0.00) h when 97/78 was given alone. While upon co- Table 1 Comparative PK parameters of 97/63 after 97/78 alone and coadministration with rifabutin in male and female rats (mean ± SEM, n = 3). administration with rifabutin these values were found (0.17 ± 0.03) mg/mL and (1.83 ± 1.25) h for C max and T max respectively. Figure 3 represents plasma concentration-time profile of 97/63, when 97/78 was given alone and in combination with rifabutin in female rats.
Female rats
In-vitro drug interaction studies
In-vitro metabolism study
The experiment was carried out to determine the non-specific binding of 97/63 with microsomal proteins. Non-specific binding was predicted from the disappearance of 97/63, upon its incubation in an optimized incubation milieu of rat liver microsomes at various concentrations ranging from 0.1 to 20 mM for 5, 10, 15 min. It revealed that there were non-significant protein-ligand interactions (data not shown). Figure 4 represents the % drug remaining upon incubation of 97/63 alone and 97/63 with rifabutin in optimized microsomal mixture at various time intervals. Table 2 represents % plasma protein binding of 97/63, when spiked alone and with rifabutin in SD rat plasma. It was found that there is slight increase in 97/63 metabolism when 97/63 was incubated with rifabutin, compared to metabolism of 97/63 upon alone incubation. Figure 5 represents plasma concentration-time profile of 97/ 63, when 97/78 was given alone in male and female rats.
In-vitro plasma protein binding study
On the other hand, when 97/78 was co-administered with rifabutin in male rats, statistically significant differences were reported in PK parameters of 97/63. It was observed that rifabutin co-administration reduced systemic exposure of 97/63 by a factor of 3-4. In terms of AUC 0-last , the value was (4.03 ± 0.60) mg h mL −1 when 97/78 was given alone, while it was decreased to (1.13 ± 0.10) mg h mL 
Discussion
It is important to assess drug's safety and effectiveness during the drug development phase in terms of drug interactions between investigational new drug and other drugs, so as to define existence of any potential DDIs that in turn indicates the need for additional therapeutics monitoring, dose adjustments and/or contraindication to concurrent use [8] . Generally, the more the number of drugs is given simultaneously the greater is the potential of existence of DDIs. Keeping this in view, the study was designed to determine the influence of rifabutin coadministration on PK of 97/63 in male and female SD rats to assess co-administered and intersexual differences.
It was found that 97/63 exhibited irregular plasma concentration-time profile in both the genders when 97/78 was either given alone or with rifabutin. However, when 97/78 was given alone, there were no intersexual differences in PK parameters of 97/63 i.e., both the genders exhibited similar PK profile as evident from the data in our study. Though, the value of C max in female rats was found to be greater than male rats, but the difference was statistically non-significant in terms of P > 0.05. All other PK parameters were comparable for both the genders.
On the other hand, when 97/78 was co-administered with rifabutin in male rats, statistically significant differences were reported in PK parameters of 97/63. It was observed that rifabutin co-administration reduced systemic exposure of 97/63 by a factor of 3-4. In the similar manner, 3-4 fold decrease was observed in C max which is explicitly indicated by the reduced maximum plasma concentration of 97/63 from (0.56 ± 0.18) to (0.13 ± 0.03) mg/mL upon rifabutin co-administration. Statistically significant difference was also observed for T max values. However, T 1/2 and MRT values were comparable in both the cases i.e. no significant differences were observed.
Similarly, in female rats statistically significant differences were reported in PK parameters of 97/63 when 97/78 was coadministered with rifabutin. It was observed that rifabutin coadministration reduced systemic exposure of 97/63 by a factor of 3-4 like male rats. In terms of AUC 0-last , the value was (5.44 ± 1.15) mg$h$mL −1 when 97/78 was given alone, while it was decreased to (1.23 ± 1.13) mg h mL upon rifabutin co-administration in females too, indicating 3-4 fold decrease in C max . Statistically significant difference was observed for T max values, while T 1/2 and MRT values were comparable in both the cases i.e. no significant differences were observed.
As discussed earlier, no significant differences (in terms of Pvalue) were observed in PK parameters of 97/63 when 97/78 was given alone in male and female rats i.e., no intersexual influences were reported. In the similar way, when rifabutin was co-administered with 97/78, no intersex differences were observed in the interaction pattern. In both the genders, 3-4 fold decrease was reported in the systemic exposure of 97/63 upon rifabutin co-administration with 97/78.
Overall, in-vivo studies have shown that there was a significant decrease in the systemic exposure of 97/63 upon rifabutin co-administration in both the sexes. However, we hypothesized that there could be multi-fold decrease in the systemic exposure of 97/63, when 97/78 would have been co-administered with rifabutin for long duration, since rifabutin is a moderate inducer of hepatic CYP 3A. Thus, a multiple dose study may be required to estimate and explore these aspects of interactions. The results of our study thus provide a basic information about the existence of drug interactions between rifabutin and 97/78, which can be used to conduct a multiple dose drug interaction study.
Further, we exercised to find out the mechanism behind the existence of interaction between 97/78 and rifabutin in-vitro. Invitro metabolism studies in rat liver microsome revealed that upon rifabutin co-incubation with 97/63, there was 10%-12% increase in the metabolism of 97/63 compared to 97/63 incubation alone. It was found that about 48% of 97/63 get metabolized upon alone incubation, compared to about 60% metabolism of 97/63 upon rifabutin co-incubation. Thus, it could be reasoned that the decreased systemic exposure of 97/63 upon rifabutin coadministration can be in-part attributed to the increased metabolism of 97/63 in presence of rifabutin. However, others factors like interference in the absorption may be one among the reasons responsible for decreased systemic exposure of 97/63.
In-vitro plasma protein binding studies have shown that there was a very strong displacement of 97/63 from plasma proteins when 97/63 was added with rifabutin into rat plasma. The extent of plasma protein binding of 97/63 was found to be decreased from 54% to 55% to a very low value of 6%-8% upon rifabutin addition. It could be speculated from the results of plasma protein bindings that upon displacement of 97/63 from plasma proteins, the increased free drug concentration of 97/63 is more susceptible to extraction by hepatocytes and hence more liable to get metabolized by hepatic CYPs, thus contributing to the decrease in the systemic exposure of 97/63.
From the above discussion, it could be concluded that rifabutin co-administration altered PK parameters of 97/63 in SD rats. A significant decrease was reported in the systemic exposure of 97/ 63, which indicates that the combination of these two drugs may require some dose adjustments. However, no intersexual influences were reported in the interaction pattern. The results of invivo interaction studies were well correlated with in-vitro studies and attempts were made to explain the mechanism behind the existence of drug interaction. Though this was a single dose interaction study in SD rats, multiple dose drug interaction study can be conducted on the basis of the informations obtained in this study. Further, clinical studies are required to determine the potential of these drug interactions in humans. The results obtained in this study can be extrapolated to humans using proper simulation models keeping in view all the gender and species differences in relation to physio-chemical variations.
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